Vertex Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2012. For the quarter, the company reported total revenues of $333,994,000 compared to total revenues of $563,340,000 for the same period a year ago. Loss from operations was $77,476,000 compared to income from operations of $223,902,000 last year. Loss before benefit from income taxes was $80,772,000 compared to income before provision for income taxes of $210,801,000 last year. Net loss was $78,076,000 compared to net income of $188,141,000 last year. Net loss attributable to the company was $76,148,000 or $0.35 per basic and diluted share compared to net profit attributable to the company of $158,629,000 or $0.74 per diluted share last year. Non GAAP income from operations was $11,137,000 compared to income from operations of $192,291,000 last year. Non GAAP net profit attributable to the company was $8,969,000 or $0.04 per diluted share compared to $185,197,000 or $0.86 per diluted share last year. Non GAAP income before provision for income taxes was $7,598,000 compared to income before provision for income taxes of $188,346,000 last year.

For the year, the company reported total revenues of $1,527,042,000 compared to total revenues of $1,410,626,000 for the same period a year ago. Income from operations was $2,332,000 compared to income from operations of $113,820,000 last year. Loss before benefit from income taxes was $12,381,000 compared to income before provision for income taxes of $60,445,000 last year. Net loss was $51,135,000 compared to net income of $41,179,000 last year. Net loss attributable to the company was $107,032,000 or $0.50 per basic and diluted share compared to net profit attributable to the company of $29,574,000 or $0.14 per basic and diluted share last year. Non GAAP income from operations was $271,231,000 compared to income from operations of $33,794,000 last year. Non GAAP net profit attributable to the company was $255,536,000 or $1.18 per diluted share compared to $16,116,000 or $0.08 per diluted share last year. Non GAAP income before provision for income taxes was $256,500,000 compared to income before provision for income taxes of $19,265,000 last year.

The company expects full-year 2013 total revenues to be in the range of $1.10 billion to $1.25 billion, including full-year 2013 KALYDECO net revenues of $280 million to $320 million. The growth of 2013 KALYDECO revenues, compared to full-year 2012 revenues of $172 million, is primarily dependent on completion of reimbursement discussions in countries outside the U.S.